GPT and metabolic dysfunction-associated steatohepatitis: In the Pioglitazone vs. Vitamin E vs. Placebo for Treatment of Non-Diabetic Patients With Nonalcoholic Steatohepatitis (PIVENS) trial (ClinicalTrials.gov Identifier: NCT00063622), pioglitazone treatment resulted in a positive decrease of in liver enzymes (aspartate aminotransferase -AST, alanine aminotransferase -ALT), fatty liver and lobular inflammation in NonAlcoholic SteatoHepatitis (NASH) patients, possibly due to an improvement in small dense lipoproteins [30].